title: Elderly woman with triple-negative metastatic breast cancer successfully treated with metronomic capecitabine.
abstract: Triple-negative breast cancer phenotype (estrogen receptor-, progesterone receptor- and human epidermal growth receptor 2-negative) is one of the most aggressive molecular subtypes, accounting for 15-20% of all breast tumors. There is no standard treatment for this setting of patients except anthracyclines and taxanes, but not all elderly patients can tolerate these kinds of agents. We describe the case of an elderly woman affected by triple-negative breast cancer with bone and brain metastases who has been treated for five years with metronomic capecitabine. At the moment, the patient has stable disease and enjoys good quality of life. She had initially been diagnosed with a poor Karnofsky index, which has actually improved from 50 to 90. Metronomic capecitabine treatment has clearly improved her quality of life, as documented by the results of the Functional Assessment of Cancer Therapy Breast.
authors: Department of Experimental Medicine, Sapienza University of Rome, Rome, Sapienza, Italy.
authors: Francesca
authors: F
authors: De Iuliis
authors: Department of Experimental Medicine, Sapienza University of Rome, Rome, Sapienza, Italy.
authors: Gerardo
authors: G
authors: Salerno
authors: Department of Experimental Medicine, Sapienza University of Rome, Rome, Sapienza, Italy.
authors: Ludovica
authors: L
authors: Taglieri
authors: Department of Cardiovascular, Respiratory, Nephrologic, Anesthesiologic and Geriatric Sciences, Sapienza University of Rome, Rome, Sapienza, Italy.
authors: Roberto
authors: R
authors: Vicinanza
authors: Department of Gynecology and Obstetrics, Sapienza University of Rome, Rome, Sapienza, Italy.
authors: Rosina
authors: R
authors: Lanza
authors: Department of Experimental Medicine, Sapienza University of Rome, Rome, Sapienza, Italy susanna.scarpa@uniroma1.it.
authors: Susanna
authors: S
authors: Scarpa
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage* / Q000009:adverse effects; D001859:Bone Neoplasms / Q000556:secondary; D001932:Brain Neoplasms / Q000556:secondary; D000069287:Capecitabine; D003841:Deoxycytidine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D006801:Humans; D011788:Quality of Life; D014057:Tomography, X-Ray Computed; D064726:Triple Negative Breast Neoplasms / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000473:pathology / Q000523:psychology
chemical_list: D000964:Antimetabolites, Antineoplastic; D003841:Deoxycytidine; D000069287:Capecitabine; D005472:Fluorouracil
keywords: FACT-B; T-negative breast cancer; bone metastasis; brain metastasis; capecitabine; metronomic chemotherapy; quality of life; stereotactic radiosurgery